The present invention relates to a blood coagulation factor Ⅶ derivative, a blood coagulation factor Ⅶa derivative, FacⅦ and FacⅦa conjugates each prepared by linking a polymer capable of extending the blood half-life to the derivative, FacⅦ and Ⅶa complexes each prepared by linking a carrier to the conjugate, genes encoding the FacⅦ and FacⅦa derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the FacⅦ and FacⅦa derivatives using the transformants, a method for preparing the FacⅦa conjugate and complex, a FacⅦa complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient. Further, the present invention relates to a method for preventing or treating hemophilia or for promoting blood coagulation, comprising administering to a subject a therapeutically effective amount of the composition. The FacⅦ or FacⅦa derivative of the present invention is able to bind with a carrier capable of improving the blood half-life while maintaining the activity of FacⅦ or FacⅦa, and they can be widely used in the development of effective prophylactic or therapeutic agent for hemophilia.La présente invention concerne un dérivé du facteur VII de coagulation sanguine, un dérivé du facteur VIIa de coagulation sanguine, des conjugués de FacVII et FacVIIa chacun préparé par la liaison dun polymère apte à étendre la demi-vie dans le sang du dérivé, des complexes FacVII et VIIa chacun préparé par la liaison dun support au conjugué, des gènes codant pour les dérivés de FacVII et FacVIIa, des vecteurs dexpression comprenant les gènes, des transformants introduits avec les vecteurs dexpression, un procédé de préparation des dérivés de FacVII et FacVIIa à laide des transformant
